Tests endovascular therapy for stroke caused by a blocked M2 brain artery
Tests a clot-removal procedure in adults with a sudden stroke from a blocked brain artery.
Plain-language title generated from the registry record
Registry title: Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery
Key facts
- Where
- Nishinomiya, JapanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 84 years old?
Source: NCT07347665, who can take part
Where in Japan
- Hyogo Medical UniversityNishinomiya, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hyogo Medical University
- Trial code
- NCT07347665
- Record updated
- 17 July 2026
- Original description
RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.Read full original descriptionShow less
Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery (the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-M2 Occlusion Trial: RESCUE-M2O Trial)
RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.
Inclusion: Acute cerebral infarction; Aged 18-84 years; NIHSS score at admission ≥ 8; Prestroke mRS scores of 0-1 (able to carry out all usual activities); Occlusion of the M2 segment of MCA on digital subtraction angiography; ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8; Ineligible or failed intravenous tPA (no recanalization within 30 min after injection); Randomization can be completed within 24 h from the last known well time; EVT can be initiated within 30 min from randomization; The patient or their legally authorized representative has signed the informed consent form.
Exclusion: Known allergy (more severe than skin rash) to contrast agents; Evidence of acute intracranial hemorrhage on CT (or MRI); High risk of hemorrhage (platelet < 40,000/ul, APTT > 50 sec or PT-INR > 3.0); Occlusion of the anterior temporal artery, duplicate M1, or accessory M1; Occlusion of multiple major intracranial arteries; Difficulty in endovascular access due to tortuous vascular anatomy; Significant mass effect with midline shift on CT (or MRI); Pregnant or potentially pregnant; Clinical evidence of chronic occlusion; Participating in any other therapeutic investigational trial; Judgment of the investigator to be non-compliant or uncooperative during the study.